Press releases

Press releases

Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics

Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners

Read More »
Press releases

Inotrem Announces Fast Track Designation Granted by U.S. FDA to Nangibotide development program for the Treatment of Septic Shock

Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide development program for the treatment of septic shock. Nangibotide, which Phase IIb has just been

Read More »
Press releases

Inotrem announces FDA clearance of Investigational New Drug (IND) for the phase IIB ASTONISH trial in septic shock patients to demonstrate nangibotide efficacy

Paris (France). August 6. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for the ASTONISH trial (Phase IIb) where the safety, tolerance and efficacy of nangibotide (LR12),

Read More »

Inotrem announces positive results from the Phase IIa study of its lead compound, nangibotide (LR12), in the treatment of septic shock.

The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the

Read More »

Martin Koch joins Inotrem as Chief Operating Officer

Paris, January 18th . 2018. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO). Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining

Read More »

Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test

Paris, November 10, 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, today announced a R&D collaboration agreement with Roche Diagnostics to develop a companion diagnostic test using a soluble plasma circulating protein (sTREM-1) developed by Inotrem and the Roche proprietary

Read More »

Inotrem announces new preclinical data supporting its lead compound’s (LR12) positive role on vascular dysfunction during septic shock

Paris, September 13 th. 2017. Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today that preclinical results show a direct and strong protective effect of its lead product candidate LR12 on vascular function during experimental septic shock. The firm was

Read More »

Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock.

Paris, France, September 13, 2016 – Inotrem SA, a biotechnology company specialized in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers. The principal objective of this first in-man phase I clinical trial, conducted

Read More »